Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Biphenyl Compound. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN114031475A enables green biaryl synthesis using ultra-low palladium and water. Achieve significant cost reduction and supply reliability.
Patent CN102267848A reveals a high-yield Suzuki coupling method using ultra-low loading nano Pd catalyst. Discover cost-effective strategies for biphenyl intermediate manufacturing.
Patent CN102351620A reveals a ligand-free nano-palladium catalyst for efficient Suzuki coupling, offering significant cost reduction and supply chain reliability for pharmaceutical intermediate manufacturing.
Patent CN1219756C details a novel Suzuki coupling method using formate additives to suppress dimer impurities, offering cost reduction in API manufacturing and enhanced supply chain reliability.
Novel coumarin-biphenyl compounds for hypertension treatment. High-yield synthesis via click chemistry. Reliable supply for API development and cost reduction.
Novel zinc-mediated debromination process for biphenyl compounds offers high yield and mother liquor recycling for cost-effective Sartan intermediate manufacturing.
Novel Pd-Cu catalytic method ensures high yield and safety for pharmaceutical intermediate manufacturing supply chain cost reduction and enhanced process scalability for global buyers.
Patent CN104844476B reveals advanced biphenyl synthesis. Offers supply chain reliability and cost reduction in pharmaceutical intermediates manufacturing.
Patent CN104311377B reveals copper-catalyzed biphenyl synthesis. Offers cost reduction and supply chain reliability for pharmaceutical intermediates manufacturing.
Patent CN105152826B enables high-purity biphenyl intermediates with >96% yield, reducing manufacturing costs and lead times for pharmaceutical supply chains.
Discover how air-promoted nanopalladium Suzuki coupling in PEG eliminates inert gas needs, reduces costs, and achieves 99% yields for pharmaceutical intermediates.